Dexdor

Pays: Union européenne

Langue: anglais

Source: EMA (European Medicines Agency)

Achète-le

Ingrédients actifs:

Dexmedetomidine hydrochloride

Disponible depuis:

Orion Corporation

Code ATC:

N05CM18

DCI (Dénomination commune internationale):

dexmedetomidine

Groupe thérapeutique:

Psycholeptics

Domaine thérapeutique:

Conscious Sedation

indications thérapeutiques:

For sedation of adult intensive care unit patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale (RASS) 0 to -3).

Descriptif du produit:

Revision: 16

Statut de autorisation:

Authorised

Date de l'autorisation:

2011-09-15

Notice patient

                                24
B. PACKAGE LEAFLET
25
PACKAGE LEAFLET: INFORMATION FOR THE USER
DEXDOR 100 MICROGRAMS/ML CONCENTRATE FOR SOLUTION FOR INFUSION
dexmedetomidine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS MEDICINE
BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or nurse.
-
If you get any side effects, talk to your doctor. This includes any
possible side effects not listed
in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1.
What Dexdor is and what it is used for
2.
What you need to know before you are given Dexdor
3.
How to use Dexdor
4.
Possible side effects
5.
How to store Dexdor
6.
Contents of the pack and other information
1.
WHAT DEXDOR IS AND WHAT IT IS USED FOR
Dexdor contains an active substance called dexmedetomidine which
belongs to a medicine group
called sedatives. It is used to provide sedation (a state of calm,
drowsiness or sleep) for adult patients
in hospital intensive care settings or awake sedation during different
diagnostic or surgical procedures.
2.
WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN DEXDOR
YOU MUST NOT BE GIVEN DEXDOR
-
if you are allergic to dexmedetomidine or any of the other ingredients
of this medicine (listed in
section 6)
-
if you have some disorders of heart rhythm (heart block grade 2 or 3)
-
if you have very low blood pressure which does not respond to
treatment
-
if you have recently had a stroke or other serious condition affecting
blood supply to the brain.
WARNINGS AND PRECAUTIONS
Before you have this medicine, tell your doctor or nurse if any of the
following apply as Dexdor
should be used cautiously:
-
if you have an abnormally slow heart rate (either due to illness or
high levels of physical fitness)
as it may increase the risk for cardiac arrest
-
if you have low blood pressure
-
if you have low blood volume, for example after bleeding
-
if you have certain heart disorders
-
if you are elderly
-
if you have a neurological disorder (for instance head o
                                
                                Lire le document complet
                                
                            

Résumé des caractéristiques du produit

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Dexdor 100 micrograms/ml concentrate for solution for infusion
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 1 ml of concentrate contains dexmedetomidine hydrochloride
equivalent to 100 micrograms
dexmedetomidine.
Each 2 ml ampoule contains 200 micrograms of dexmedetomidine.
Each 2 ml vial contains 200 micrograms of dexmedetomidine.
Each 4 ml vial contains 400 micrograms of dexmedetomidine.
Each 10 ml vial contains 1 000 micrograms of dexmedetomidine.
The concentration of the final solution after dilution should be
either 4 micrograms/ml or
8 micrograms/ml.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Concentrate for solution for infusion (sterile concentrate).
The concentrate is a clear, colourless solution, pH 4.5–7.0
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
For sedation of adult ICU (Intensive Care Unit) patients requiring a
sedation level not deeper than
arousal in response to verbal stimulation (corresponding to Richmond
Agitation-Sedation Scale
(RASS) 0 to -3).
For sedation of non-intubated adult patients prior to and/or during
diagnostic or surgical procedures
requiring sedation, i.e. procedural/awake sedation.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
FOR SEDATION OF ADULT ICU (INTENSIVE CARE UNIT) PATIENTS REQUIRING A
SEDATION LEVEL NOT DEEPER
THAN AROUSAL IN RESPONSE TO VERBAL STIMULATION (CORRESPONDING TO
RICHMOND AGITATION-SEDATION
SCALE (RASS) 0 TO -3).
For hospital use only. Dexdor should be administered by healthcare
professionals skilled in the
management of patients requiring intensive care.
Posology
Patients already intubated and sedated may switch to dexmedetomidine
with an initial infusion rate of
0.7 micrograms/kg/h which may then be adjusted stepwise within the
dose range 0.2 to
1.4 micrograms/kg/h in order to achieve the desired level of sedation,
depending on the patient’s
response. A lower starting infusion rate should be considered for
frail patients. Dexmedetomid
                                
                                Lire le document complet
                                
                            

Documents dans d'autres langues

Notice patient Notice patient bulgare 14-07-2022
Rapport public d'évaluation Rapport public d'évaluation bulgare 01-10-2018
Notice patient Notice patient espagnol 14-07-2022
Rapport public d'évaluation Rapport public d'évaluation espagnol 01-10-2018
Notice patient Notice patient tchèque 14-07-2022
Rapport public d'évaluation Rapport public d'évaluation tchèque 01-10-2018
Notice patient Notice patient danois 14-07-2022
Rapport public d'évaluation Rapport public d'évaluation danois 01-10-2018
Notice patient Notice patient allemand 14-07-2022
Rapport public d'évaluation Rapport public d'évaluation allemand 01-10-2018
Notice patient Notice patient estonien 14-07-2022
Rapport public d'évaluation Rapport public d'évaluation estonien 01-10-2018
Notice patient Notice patient grec 14-07-2022
Notice patient Notice patient français 14-07-2022
Rapport public d'évaluation Rapport public d'évaluation français 01-10-2018
Notice patient Notice patient italien 14-07-2022
Rapport public d'évaluation Rapport public d'évaluation italien 01-10-2018
Notice patient Notice patient letton 14-07-2022
Rapport public d'évaluation Rapport public d'évaluation letton 01-10-2018
Notice patient Notice patient lituanien 14-07-2022
Rapport public d'évaluation Rapport public d'évaluation lituanien 01-10-2018
Notice patient Notice patient hongrois 14-07-2022
Rapport public d'évaluation Rapport public d'évaluation hongrois 01-10-2018
Notice patient Notice patient maltais 14-07-2022
Rapport public d'évaluation Rapport public d'évaluation maltais 01-10-2018
Notice patient Notice patient néerlandais 14-07-2022
Rapport public d'évaluation Rapport public d'évaluation néerlandais 01-10-2018
Notice patient Notice patient polonais 14-07-2022
Rapport public d'évaluation Rapport public d'évaluation polonais 01-10-2018
Notice patient Notice patient portugais 14-07-2022
Rapport public d'évaluation Rapport public d'évaluation portugais 01-10-2018
Notice patient Notice patient roumain 14-07-2022
Rapport public d'évaluation Rapport public d'évaluation roumain 01-10-2018
Notice patient Notice patient slovaque 14-07-2022
Rapport public d'évaluation Rapport public d'évaluation slovaque 01-10-2018
Notice patient Notice patient slovène 14-07-2022
Rapport public d'évaluation Rapport public d'évaluation slovène 01-10-2018
Notice patient Notice patient finnois 14-07-2022
Rapport public d'évaluation Rapport public d'évaluation finnois 01-10-2018
Notice patient Notice patient suédois 14-07-2022
Rapport public d'évaluation Rapport public d'évaluation suédois 01-10-2018
Notice patient Notice patient norvégien 14-07-2022
Notice patient Notice patient islandais 14-07-2022
Notice patient Notice patient croate 14-07-2022
Rapport public d'évaluation Rapport public d'évaluation croate 01-10-2018

Rechercher des alertes liées à ce produit

Afficher l'historique des documents